Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host

Blood

Volumn 109, Issue 10, 2007, Pages 4336-4342

  Liu, Cunren ^a   Yu, Shaohua ^a   Kappes, John ^b   Wang, Jianhua ^a   Grizzle, William E ^c   Zinn, Kurt R ^d   Zhang, Huang Ge ^a,e,f  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d The University of Alabama at Birmingham   (United States)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B; PERFORIN; STAT5 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL COMPOSITION; CELL CONTACT; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME SYNTHESIS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; IMAGE ANALYSIS; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL;

EID: 34248342290     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-09-046201     Document Type: Article

References (37)

1. Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006;116:2777-2790.
2. Frey AB. Myeloid suppressor cells regulate the adaptive immune response to cancer. J Clin Invest. 2006;116:2587-2590.
3. Kim R, Emi M, Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology. 2006;119:254-264.
4. Valenti R, Huber V, Filipazzi P, et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 2006;66:9290-9298.
5. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 2006;176:284-290.
6. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66:1123-1131.
7. Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol. 2006;176:2085-2094.
8. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006;66:9299-9307.
9. Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202:931-939.
10. Yang R, Cai Z, Zhang Y, Yutzy WH 4th, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res. 2006;66:6807-6815.
11. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 2005;174:4880-4891.
12. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother. 2002;51:293-298.
13. Bronte V, Serafini P, Apolloni E, Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother. 2001;24:431-446.
14. Serafini P, De Santo C, Marigo I, et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother. 2004;53:64-72.
15. Guven H, Gilljam M, Chambers BJ, et al. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia. 2003;17:1973-1980.
16. Koizumi S, Seki H, Tachinami T, et al. Malignant clonal expansion of large granular lymphocytes with a Leu-11+, Leu-7- surface phenotype: in vitro responsiveness of malignant cells to recombinant human interleukin 2. Blood. 1986;68:1065-1073.
17. Liu C, Yu S, Zinn K, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol. 2006;176:1375-1385.
18. Ribas A, Wargo JA, Comin-Anduix B, et al. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol. 2004;172:4762-4769.
19. Roszkowski PI, Hyc A, Malejczyk J. Natural killer cell activity in patients with ovarian tumors and uterine myomas. Eur J Gynaecol Oncol. 1993;14(suppl):114-117.
20. Rouas-Freiss N, Paul P, Dausset J, Carosella ED. HLA-G promotes immune tolerance. J Biol Regul Homeost Agents. 2000;14:93-98.
21. Wilson SD, McCay JA, Butterworth LF, Munson AE, White KL Jr. Correlation of suppressed natural killer cell activity with altered host resistance models in B6C3F1 mice. Toxicol Appl Pharmacol. 2001;177:208-218.
22. Wu TY, Fleischmann WR Jr. Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved. J Interferon Cytokine Res. 2001;21:1117-1127.
23. Zhang HG, Zhou T, Yang P, Edwards CK 3rd, Curiel DT, Mountz JD. Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum Gene Ther. 1998;9:1875-1884.
24. Grizzle WE, Mountz JD, Yang PA, et al. BXD recombinant inbred mice represent a novel T cell-mediated immune response tumor model. Int J Cancer. 2002;101:270-279.
25. Barao I, Vaz F, Almeida-Porada G, Srour EF, Zanjani ED, Ascensao JL. Human natural killer cell development in a xenogeneic culture system. Br J Haematol. 2002;118:885-892.
26. Borg C, Jalil A, Laderach D, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood. 2004;104:3267-3275.
27. Zhang Y, Wang Y, Ogata M, Hashimoto S, Onai N, Matsushima K. Development of dendritic cells in vitro from murine fetal liver-derived lineage phenotype-negative c-kit(+) hematopoietic progenitor cells. Blood. 2000;95:138-146.
28. Zhang HG, Hyde K, Page GP, et al. Novel tumor necrosis factor alpha-regulated genes in rheumatoid arthritis. Arthritis Rheum. 2004;50:420-431.
29. Brooks JC, Hoskin DW. The inhibitory effect of cyclophosphamide-induced MAC-1+ natural suppressor cells on IL-2 and IL-4 utilization in MLR. Transplantation. 1994;58:1096-1103.
30. Cheng F, Gabrilovich D, Sotomayor EM. Immune tolerance in breast cancer. Breast Dis. 2004;20:93-103.
31. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11:6713-6721.
32. Romagnani C, Della Chiesa M, Kohler S, et al. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol. 2005;35:2452-2458.
33. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol. 2004;173:3716-3724.
34. Darnell JE Jr. The JAK-STAT pathway: summary of initial studies and recent advances. Recent Prog Horm Res. 1996;51:391-403; discussion 403-394.
35. Goebel J, Forrest KJ, Mikovits J, Emmrich F, Volk HD, Lowry RP. STAT5 pathway: target of anti-CD4 antibody in attenuation of IL-2 receptor signaling. Transplantation. 2001;71:792-796.
36. Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene. 2000;19:2566-2576.
37. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 2000;19:2496-2504.